Quick Answer
SANGAMO THERAPEUTICS, INC reported Revenue From Contract With Customer Excluding Assessed Tax of $39.55 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -31.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), SANGAMO THERAPEUTICS, INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 104.0%.
- Historical annual values: Fiscal year 2025: $39.55 million | Fiscal year 2024: $57.80 million | Fiscal year 2023: $176.23 million | Fiscal year 2022: $111.30 million | Fiscal year 2021: $110.70 million | Fiscal year 2020: $118.19 million | Fiscal year 2019: $102.43 million | Fiscal year 2018: $84.45 million | Fiscal year 2017: $36.57 million | Fiscal year 2016: $19.39 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: